PneumRx

PneumRx is developing and marketing a minimally invasive device to treat emphysema. This innovative implantable device, the RePneu® Lung Volume Reduction Coil (LVRC™), is designed to improve lung function in patients with emphysema by reducing lung volume. The RePneu LVRC is implanted through a bronchoscope in a simple and short procedure, under conscious sedation or general anesthesia. There is a high unmet medical need for severe emphysema patients as drugs have limited therapeutic efficacy.


Recent News

January 4, 2011
PneumRx, Inc. Raises $33 Million in Capital

 


Company Info
 
Country: USA
Industry:    LS
Sector: medical technology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Erin McGurk, CEO


Company website
 www.pneumrx.com


Endeavour Vision Team
 
Daniel Bertholet
Damien Tappy
© Endeavour Vision SA 2006-2012 Terms & Conditions